Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for myeloma patients who stopped responding to standard treatment

NCT ID NCT05060627

First seen May 15, 2026 · Last updated May 23, 2026 · Updated 2 times

Summary

This study tests a new combination of three drugs (belantamab mafodotin, carfilzomib, and dexamethasone) in people whose multiple myeloma has come back and no longer responds to lenalidomide. The goal is to find the safest dose and see how well the combo controls the cancer. About 60 adults will take part, and treatment continues until the disease worsens or side effects become too severe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Clínica Universidad de Navarra (CUN)

    Pamplona, Spain

  • Complejo Hospitalario Santiago (CHUS)

    Santiago de Compostela, Spain

  • Complejo Hospitalario Virgen del Rocío

    Seville, Spain

  • H. Gregorio Marañón

    Madrid, Spain

  • H. Morales Meseguer

    Murcia, Spain

  • H. Son Llatzer

    Palma de Mallorca, Spain

  • H. Universitario Marqués de Valdecilla

    Santander, Spain

  • H. Universitario de Canarias

    Santa Cruz de Tenerife, Spain

  • H.U. La Fe

    Valencia, Spain

  • HUCA

    Oviedo, Spain

  • Hospital Clinic

    Barcelona, Spain

  • Hospital Germans Trias i Pujol (ICO BADALONA)

    Badalona, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario de Salamanca

    Salamanca, Spain

  • ICO Duran i Reynals

    L'Hospitalet de Llobregat, Spain

Conditions

Explore the condition pages connected to this study.